| Popis: |
SI Figure 1: Reaction scheme for synthesizing 1-(4-astatophenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one ([211At]MM4) from tin precursor 1-(4-(tributylstannyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; SI Figure 2: Reverse competitive inhibition curve; SI Figure 3: In vitro screen and dose response curves of cancer cell lines for sensitivity to [211At]MM4; SI Figure 4: Dose response curves for non-radioactive PARP inhibitors in neuroblastoma cell lines; SI Figure 5: Single cell immunofluorescence for PARP-1 and γH2AX in NLF and SK-N-BE(2)-C cell lines after treatment with 37 kBq/mL [211At]MM4 for 1 or 4 h; SI Figure 6: Single cell immunofluorescence for PARP-1 and γH2AX in SK-N-BE2, IMR-05, and SK-N-SY5Y cell lines after treatment with 37 kBq/mL [211At]MM4 for 1, 4, or 24 h; SI Figure 7: Fluorescent western blot for PARP-1, cleaved PARP-1, and γH2AX after treatment with 37 kBq/mL of [211At]MM4 for 1, 4, or 24 h; SI Figure 8: Double strand DNA breaks quantified by measuring phosphorylation of ATM and H2AX after treatment with 37 kBq/mL of [211At]MM4 for 1, 4, or 24 h; SI Figure 9: Cell cycle analysis after treatment with 37 kBq/mL of [211At]MM4 for 1, 4, or 24 h; SI Figure 10: Animal weights from A) single dose efficacy study and B) high dose vs. fractionated therapy; SI Table 1: Cell lines evaluated in this study, their culture media, and relevant mutations; SI Table 2: EC50 values for [211At]MM4 vs. non-targeted radioactive controls; SI Table 3: EC50 values for [211At]MM4 in ovarian cancer cell lines; SI Table 4: EC50 values in molar concentrations for [211At]MM4 vs. non radioactive analogue KX1; SI Table 5: EC50 values for PARP inhibitors in neruoblastoma cell lines; SI Table 6: EC50 values for PARP inhibitors in neruoblastoma cell lines |
